肿瘤细胞治疗研究
英文原题：Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer.
Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于 CAR-T 细胞疗法在治疗血液系统恶性肿瘤中的显著成功，其广泛用于实体瘤似乎也颇具前景，但仍需克服若干重要障碍。其中一项关键挑战是识别癌细胞上的特异性靶抗原。低甲基化是许多肿瘤类型的一种典型表观遗传异常。对肿瘤中一致性 DNA 低甲基化进行全基因组筛查，可识别异常上调的转录本，这些转录本可能编码细胞表面蛋白。因此，这一方法为几乎所有肿瘤类型发现潜在新型 CAR-T 靶抗原提供了新思路。本文首先聚焦于将这一方法用于前列腺癌治疗的可能性。
Based on the impressive success of Car-T-cell therapy in the treatment of hematological malignancies, a broad application for solid tumors also appears promising.
However, some important hurdles need to be overcome. One of these is certainly the identification of specific target antigens on cancer cells. Hypomethylation is a characteristic epigenetic aberration in many tumor entities. Genome-wide screenings for consistent DNA hypomethylations in tumors enable the identification of aberrantly upregulated transcripts, which might result in cell surface proteins.
Thus, this approach provides a new perspective for the discovery of potential new Car-T-cell target antigens for almost every tumor entity. First, we focus on this approach as a possible treatment for prostate cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
